Everyone has a right to feel well

Aureum Life aims to become a leading researcher and producer of medical cannabis in Sweden. What drives us is the desire to relieve the symptoms of several serious diseases. We do this by developing new raw materials, and creating carefully formulated, tested medical products.

Medical cannabis – helping more and more people

Medical cannabis – helping more and more people

Medical cannabis in Sweden is undergoing a quite dramatic development, from the first prescription in 2011 to some 100 patients in 2015, and almost 500 in 2018.

All our forecasts indicate that more than 4,000 patients in Sweden will be treated with medical cannabis as soon as 2021.

Source: Läkartidningen

Is cannabis legal in Sweden?

There is currently one approved medicine in Sweden which contains cannabis extract. It is an oral spray used to relieve muscle stiffness in multiple sclerosis (MS).

If approved medicines prove insufficient a pharmacy can apply for a licence, i.e. a sales permit from the Swedish Medical Products Agency, to prescribe preparations that are not approved in Sweden. A licence application must be supported by the prescribing physician.

Patients who have a prescription containing cannabis may keep it for their own use.

For more info, see Läkemedelsverket.

»Already this year we are introducing two cannabis-based medicines in Sweden. We’re hoping they will be on the market by December 2019, once our licence applications have been approved.

The products will initially be available for licence prescription, but we will be submitting them to the Swedish Medical Products Agency to have them approved as medications.«

– Therese Nader, CEO Aureum Pharma

aureumlife-05

Symptoms

Medical cannabis can relieve the symptoms of muscle stiffness (in e.g. MS or Parkinson’s) and in some cases also helps to reduce chronic nerve pain.

The two active substances in our preparations are cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD).

Clinical studies show that a compound of CBD and a low concentration of THC boosts the medicine’s positive effect, while reducing the adverse effects and side effects.

aureumlife-07

Side effects

The use of Cannabis Sativa L +0.2% THC as per the prescribed dose provides a clinical effect, without causing tolerance, dependency or withdrawal symptoms in the patient when tapering off.

Common side effects are dizziness, tiredness and a gain/loss in appetite.

Overdosing or acute poisoning may cause hallucinations, delusions, paranoia, tachycardia, bradycardia or toxic psychosis with hypotension.

aureumlife-08

Prescription and licence only

All our medications will be available on prescription and under licence only. This means that pharmacies must apply for a licence from the Swedish Medical Products Agency and have it approved before the prescription is dispensed.

Only specialist physicians should prescribe medical cannabis, and initially only for a trial period of four weeks.

It may take up to a couple of weeks to find the right dose, during which time the patient may experience one or more side effects.

aureumlife-09

Follow our progress

Our vision is to relieve illness symptoms and meet the needs of individual patients with carefully formulated, tested and produced drugs based on plant extracts. The aim is to launch several different diagnosis-specific, symptom-relieving drugs on the market within five years.

Our news feed

Let’s grow together

At Aureum Life we work as a team – when you grow, we grow too. You know best what you’re good at and where you want your career to go. We are a research and development company bringing together pharmacists, researchers, chemists and engineers.

Careers
aureumlife-06

A growing industry

Over the next three years we will grow from a small team to more than 400 employees, with facilities around the world. We are starting our own production site in Greece in spring 2020, followed by Zimbabwe and Swaziland in autumn of the same year and Uruguay in spring 2021. The next in line are Denmark, the Netherlands and Portugal.

Invest in the future

Join us on our path

We operate in an exciting, expansive industry, one where medicine, quality of life and politics clash on an almost daily basis. There is no doubt that medical cannabis with its clinically proven efficacy is a product of the future – but the path will not be a straight one.

Our newsletter will present new recommendations, research findings and questions in the world of cannabinoids. We will of course also write about our development, operations and expansion, with the occasional item on the latest debates, gossip and more.

Stay informed!

  • This information will only be used to send you our newsletter. You can unsubscribe from our newsletter at any time. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.